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Classical determination of growth inhibition of Mycobacterium tuberculosis in macrophages and mice by
new candidate anti-TB drugs utilizes the determination of colony forming units (CFUs) from lung ho-
mogenates, a labor-intensive process requiring 2e3 weeks incubation. Qualitative analysis of tuber-
culostearic acid (TBSA), a cell wall associated biomarker found in M. tuberculosis, has been investigated
for clinical diagnosis of tuberculosis (TB) but few reports exist of attempts to quantitate TBSA. Gas
chromatographyemass spectroscopy (GCeMS/MS) was used in quantitating the derivatized methyl ester
of TBSA during growth of M. tuberculosis in axenic medium, macrophage cultures and in the lungs of
gamma interferon knockout (GKO) mice with and without exposure to anti-TB agents. The quantity of
TBSA methyl ester (TBSAME) in the absence of and following exposure to anti-TB drugs was positively
correlated with CFU in all three models. The stability of TBSA precludes its use as a surrogate for bac-
tericidal activity but its exceptional thermal stability enables lung homogenates to be autoclaved prior to
analysis. GCeMS/MS determination of TBSA is a rapid, sensitive and accurate means of detecting growth
inhibition of any strain of M. tuberculosis in cell culture and in vivo.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Quantitative analysis of Mycobacterium tuberculosis via the
determination of colony forming units (CFUs) from serially diluted
suspensions has always presented difﬁculties due to (1) the highly
hydrophobic mycobacterial cell wall which predisposes individual
bacteria in this genus to aggregate in aqueousmedia and (2) the long
generation time of this species, requiring 2e3 weeks to visualize
colonial growth. The clumping issue is only partially ameliorated
through the use of non-ionic surfactants and/or physical dispersion
such as vortexing and sonicating. Especially in the initial evaluation
of compounds for anti-TB activity in vivo where infection and
treatment times can range from weeks to months, the additional
time required for CFUdetermination further decreases the efﬁciency
of hit to lead and lead optimization efforts. Therefore, a simple, rapid
and accurate method for quantitating M. tuberculosis from cell cul-
ture and tissue homogenates should facilitate drug discovery efforts
for TB. Metabolic surrogates employed in axenic culture of
M. tuberculosis (e.g.MICdetermination) such as redox dye reduction,833 S. Wood St, Chicago, IL
693.
-NC-ND license.ﬂuorescent protein expression and intracellular ATP measurement,
lack sensitivity and/or speciﬁcity for use in samples containing low
numbers ofM. tuberculosis and high numbers of host cells or tissues.
Tuberculostearic acid (10R-methyloctadecanoic acid, TBSA,
C19H38O2) is a methyl-branched fatty acid reported as a con-
stituent of the cell wall of the genus Mycobacterium, including
M. tuberculosis,1e3 and other phylogenetically related organisms
within the suborder Corynebacterineae including the genera
Nocardia, Corynebacterium, Gordonia and Turicella.1,4,5 Compared to
mycolic acids which form clusters of high molecular weight ho-
mologs, TBSA has a favorable physico-chemical proﬁle with regard
to volatility and ionization efﬁciency, making it a superior analytical
target with respect to speciﬁcity and throughput. The detection of
TBSA in sputum specimens with gas chromatographyemass spec-
troscopy (GCeMS) has been used for rapidly diagnosing pulmonary
M. tuberculosis infection,6e9 and TBSA was detected in specimens
with tuberculous meningitis at concentrations of 25e50 fmol
(1015 mol).10 However, there have been no reports of using TBSA
as quantitative biomarker of M. tuberculosis growth, especially
in vitro drug-mediated growth inhibition in broth, in macrophage
cell models and in mouse models.
Sincemacrophages are immune effector cells in tuberculosis and
since intracellular anti-TB activity is likely required to observe ef-
ﬁcacy in the established mouse models ofM. tuberculosis infection,
G. Cai et al. / Tuberculosis 93 (2013) 322e329 323macrophage culture infection models have been used for the eval-
uation of established and experimental anti-TB agents.11,12 So we
also evaluated this infection model for drug inhibition assay with
both TBSA and CFU determination. Since gamma-interferon is
considered to be a principal mediator of macrophage activation and
essential in resistance to intracellular M. tuberculosis infection,
gamma-interferon knock-out (GKO) mice exhibit more serious tis-
sue necrosis and amore rapid and fatal tuberculosis infection.13,14 To
date GKO mice have been used in anti-TB drug efﬁcacy assays with
only CFU as the bacterial growth indicator.15e17 Here we demon-
strate that TBSA can be used to rapidly quantitateM. tuberculosis in
infectedmacrophage cells (J774) andGKOmouse lung homogenates
in a dose-dependent manner after exposure to various anti-TB
drugs.th
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2.52. Materials and methods
2.1. Sample preparation and TBSA analysis by GCeMS/MS
TBSA was obtained from the Research Institute for Chromatog-
raphy (Kortrijk, Belgium) and was derivatized to its methyl ester
(TBSAME) by a slight modiﬁcation.18,19 In detail, approximately
0.2 mg TBSAwas saponiﬁed by adding 1 ml 1.2 M NaOH and MeOH
(50%/50%) followed by autoclaving (120 C for 15 min), and
methylated with 2 ml 6 N HCl and MeOH (54%/46%) in an 80 C
water bath for 10 min followed by quick cooling. The samples were
extracted with 1.25 ml n-hexane and methyl t-butyl ether (50%/
50%), and the supernatant puriﬁed with 3 ml 0.3 M NaOH and
dehydrated with approximately 10 mg anhydrous Na2SO4. Then,
95 ml of the puriﬁed supernatant was spikedwith 5 ml nonadecanoic
acid tri-deuterated methyl ester (MND-d3) in n-hexane of known
concentration as internal standard. The internal standard was
synthesized with nonadecanoic acid (Sigma) and MeOH-d4 (Sigma)
using the same method as TBSA. TBSAME and MND-d3 elute in the
Agilent HP-5ms Capillary GC column (Agilent 19091S-433, 5%
phenyl methyl silox, 30 m  2, ID 0.25 mm, ﬁlm thickness 0.25 mm)
at 8.6 min and 9.2 min respectively within a total run of 12.6 min,
using a GC temperature ramp starting from 220 C to 280 C at
a rate of 6 C/min, then at 50 C/min to 310 C and held for 2 min.
Both TBSAME and MND-d3 were fragmented into their qualiﬁers
and quantiﬁers in an Agilent 7890A GC system linked with an
Agilent 7000A triple quadrupole mass spectrometer. Multiple Re-
action Monitoring (MRM) mode was applied with collision energy
of 10 eV: m/z 312.5 to 143 and to 199 for TBSAME, and m/z 315.5 to
104 and to 146 for MND-d3, as quantiﬁers and qualiﬁers for both
compounds respectively (Figure 1). TBSAME concentrations were
calculated with the Agilent Masshunter Quantitative software
based on a calibration curve of serially diluted TBSAME standard
solutions spiked with MND-d3.O
OCD3
146
MND-d3
104
OCH3
O
143
199 TBSAME
Figure 1. Structures and putative MS fragmentations of TBSAME and MND-d3.2.2. TBSA correlation with CFU in vitro
The H37Rv (ATCC 27294) and Erdman (ATCC 35801) strains of
M. tuberculosis were obtained from the American Type Culture
Collection (Bethesda, MD). For in vitro correlations of TBSA with
CFU, cultures were grown in Middlebrook 7H9 broth (BD Bio-
sciences) supplemented with oleic acid, albumin, dextrose, catalase
(OADC, Fisher Scientiﬁc). To determine the linearity of correlation
of TBSA with CFU, stationary phase cultures were harvested after 9
days of incubation. Six 50 ml aliquots of the culture were centri-
fuged, and the pellets were each re-suspended in 50 ml PBS buffer.
For each, ﬁve serial dilutions of 1:5 were prepared in PBS. After
removing 100 ml from one aliquot of each diluted suspension for
CFU determination on Middlebrook 7H11 agar (BD Biosciences)
with 10% OADC, the remaining 40 ml from all six aliquots at each
dilution was centrifuged, and the pellets were processed for TBSA
analysis as per the above method for converting the TBSA standard
compound to TBSAME. The concentrations of TBSAME from the
same gradient were averaged.
To monitor the correlation of TBSA with CFU during growth in
axenic medium, one milliliter of 1.7e2 107 CFU/mlM. tuberculosis
H37Rv or Erdman was inoculated into 300 ml Middlebrook 7H9
liquid culture media (with 10% OADC). At 48 h intervals for 14 days,
100 ml aliquots of culture were serially diluted for CFU determi-
nation and the remaining 30 ml sample processed as above for
quantitation of TBSA.
2.3. Drug inhibition of M. tuberculosis in axenic medium
M. tuberculosis H37Rv was incubated for 7 days in 300 ml Mid-
dlebrook 7H9 with 10% OADC in a 1 L ﬂask with shaking at 120 rpm
until early plateau phase as determined by optical density using
a Klett-Summerson colorimeter. Individual cultures received iso-
niazid (INH, Sigma) at 21, 63, and 189 ng/ml or rifampin (RMP,
Fisher Bioreagents) at 33, 99, and 296 ng/ml. Three aliquots of 25ml
were removed from each ﬂask before (Day 0) and 7 days after
addition of drugs, and each aliquot used for the determination of
CFU and for TBSA in the bacterial pellets.
2.4. Growth of M. tuberculosis Erdman in macrophages
Adherent macrophages (J774, 3rd or 4th passage) were cultured
in three 6-well plates in 5 ml Dulbecco’s Modiﬁed Eagle Media (D-
MEM, ATCC, Manassas, VA) supplemented with 10% fetal bovineLog10CFU(/ml broth)
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Figure 2. Correlation of TBSA and CFU from serially diluted M. tuberculosis H37Rv from
stationary phase culture. For TBSA and CFU each data point represents the mean of six
culture aliquots and one aliquot, respectively, each independently serially diluted.
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Figure 3. (A) TBSA and CFU during in vitro growth ofM. tuberculosis H37Rv and Erdman. Solid line with closed squares: H37Rv CFU; solid line with closed circles: H37Rv TBSA; dashed
line with open squares: Erdman CFU; dashed line with open circles: Erdman TBSA; (B) linear correlation of log10TBSA and log10CFU of M. tuberculosis H37Rv (solid line, closed dots)
and Erdman (dashed line, open dots).
G. Cai et al. / Tuberculosis 93 (2013) 322e329324serum (FBS, Atlanta biologicals, Lawrenceville, GA) and 200 U/ml
polymyxin B (Sigma). Macrophages were exposed toM. tuberculosis
Erdman suspended in D-MEM at a multiplicity of infection of
approximately 1 for one hour, and then culture media was sepa-
rated from the macrophage monolayer on the plate surface.
Extracellular M. tuberculosis was removed by washing the layer of
macrophage cells attaching to the plate twice with 5 ml warm
Hanks’ Balanced Salt Solution (HBSS, Atlanta Biologicals). The
washings, combined with the initial 5 ml culture media, were
centrifuged at 1485 g for 10 min at room temperature (Eppendorf
centrifuge 5415D, 24-place ﬁxed-angle rotor) and supernatant was2.0
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Figure 4. TBSA (AeB) and CFU (CeD) response to INH and RMP in vitro. (*0discarded. Both the media/wash pellets from the mixture of
extracellular M. tuberculosis and unattached macrophage cells and
the adherent layer of macrophages were treated with 1 ml 0.25%
SDS and incubated at 37 C for 10 min to release intracellular
M. tuberculosis. One-hundred microliters of lysate were used for
CFU determination onMiddlebrook 7H11 agar plates. Five-milliliter
warm D-MEM media was added to the remaining wells and two
wells of the 6-well plates were processed in the same manner on
days 1, 3, 5, 6 and 7 post-infection. In this manner growth curves of
M. tuberculosis were established from both adherent and ﬂoating
macrophages.L
o
g
1
0
T
B
S
A
M
E
 (
n
g
/
m
l
 b
r
o
t
h
)
0
1
2
3
4
5
6
***
******
L
o
g
1
0
C
F
U
 (
/
m
l
 b
r
o
t
h
)
0
2
4
6
8
10
***
***
***
Pre-Tx                       0             33           99          296     ng/ml
RMP
T7
B
D
.01 < p < 0.05; **0.005 < p < 0.01; ***p < 0.005 compared with CTRL).
Figure 5. (AeB) Growth and responses of TBSA and CFU in M. tuberculosis Erdman-infected macrophages to 7-day drug exposure. The drug concentrations (mg/ml) were: 0.01, 0.04
and 0.16 for RMP and INH, 0.025, 0.1 and 0.4 for moxiﬂoxacin (MOX) and PA-824 (PA), and 0.25, 1.0 and 4.0 for ethambutol (EMB). Each data point represents an individual culture;
(C) TBSA and CFU correlation for all cultures (dashed line, y ¼ 0.35x  2.93, R2 ¼ 0.45) and for only untreated control cultures (solid line, closed circles, y ¼ 1.26x  8.15, R2 ¼ 0.87).
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Table 1
Correlation of drug concentration and CFU or TBSA in macrophage infection
model.
Drug R2
CFU TBSA
RMP 0.98 0.89
INH 0.96 0.88
MOX 0.90 0.73
PA 0.77 0.77
EMB 0.02 0.86
G. Cai et al. / Tuberculosis 93 (2013) 322e3293262.5. Drug inhibition of M. tuberculosis in macrophages
One day after infection, the culture media was replaced with
freshmedia containing three 4-fold concentrations of anti-TB drugs
in D-MEM; three replicate wells were set up for each drug con-
centration and for drug-free media controls. The pellets of both
ﬂoating and adherent macrophages were combined and lysed for
CFU determination and then centrifuged for TBSA analyses. Drug-
free controls were harvested on T1, T3, T5 and T7 while drug-
treated samples were evaluated only on T7.
2.6. Growth inhibition of M. tuberculosis in gamma-interferon
knock-out (GKO) mice treated with anti-TB drugs
Ninety-two GKO mice (11 weeks old, female, Jackson Labora-
tory) were infected by aerosolization of 10 ml of a suspension
containing 2  106 CFU/ml M. tuberculosis Erdman strain using an
aerosol infection chamber (Glas Col, Terre Haute, IN). Growth was
monitored by TBSA and CFU in untreated mice at days 10, 17 and 24
post-infection. Ten days after infection, groups of 5 mice were
treated by oral gavage daily for fourteen days with one of three
two-fold dosages of RMP, INH, MOX, PA and EMB suspended in 0.5%
carboxylmethylcellulose (CMC). All drugs were administered in
200 ml CMC, except for MOX which was delivered in 100 ml, 200 ml
and 400 ml of a 1.6 mg/ml stock solution (Figure 6). Two days fol-
lowing the ﬁnal dose, mice were euthanized, both lungs removed
and homogenized in 3ml of HBSS buffer. After removal of an aliquot
for CFU determination, 2.5 ml of lung homogenates were centri-
fuged and pellets used for TBSA analysis.
3. Results
3.1. Correlation of TBSA with CFU in vitro
There was a linear correlation of log10CFU values with log10TBSA
from a serially diluted stationary phase culture of H37Rv
(R2 ¼ 0.9774, Figure 2). In growing cultures of both H37Rv and
Erdman strains (Figure 3) TBSA synthesis appears to initially lag
behind increases in CFU (Figure 3A), however the overall correla-
tion of these parameters throughout the growth curves of the two
strains were R2 ¼ 0.9112 and R2 ¼ 0.9314, respectively (Figure 3B).
No signiﬁcant differences in growth rate or TBSA concentration
were found between M. tuberculosis H37Rv and Erdman strains.
3.2. Dose-dependent inhibition of INH and RMP on M. tuberculosis
growth in bacterial broth
In axenic medium both INH and RMP effected signiﬁcant dose-
dependent inhibition of TBSA (Figure 4) while this marker
increased by 35e55 mg/ml in untreated controls over the 7-day
incubation. Despite the reduction in CFU relative to pre-treatment
values with the two higher concentrations of INH and all three
concentrations of RMP, as expected, TBSA never fell signiﬁcantly
below pre-treatment levels. The correlations (R2) of CFU and TBSA
across the concentration ranges were 0.698 for INH and 0.629 for
RMP.
3.3. Growth and drug-inhibition of M. tuberculosis in macrophage
culture
Six-well plates were used to obtain sufﬁcient quantities of
M. tuberculosis for TBSA analysis. A preliminary experiment indi-
cated that in such cultures,M. tuberculosis Erdmanwithin adherent
macrophages, increased within one day after infection and
greatly decreased after day 3 (data not shown). The number ofM. tuberculosis recovered from ﬂoating macrophages increased
slowly but continuously starting from the day of infection. Con-
sidering both M. tuberculosis residing within adherent and ﬂoating
macrophages, the total intracellular M. tuberculosis titer increased
by 0.8 log10CFU over the 7-day incubation.
In a subsequent experiment, untreated intracellular M. tuber-
culosis gradually increased throughout the 7 days of culture as
indicated by both a 0.22 mg/ml increase in TBSA concentration and
a 0.63 log10 increase in CFU. With the exception of the effect of EMB
on CFU, all drugs demonstrated a concentration-dependent inhi-
bition of both TBSA and CFU at day 7 (R2 > 0.7 for each readout).
Whereas the highest concentrations of INH and RMP appeared
bactericidal when assessed by CFU (i.e., values below that observed
on day 1), TBSA concentrations never fell below starting levels
(Figure 5AeB). The correlation between TBSA and CFU during
growth in untreated control cultures was better (R2 ¼ 0.87) than
when also considering both untreated and drug-treated cultures
(R2 ¼ 0.45) (Figure 5C; Table 1).
3.4. Inhibition of M. tuberculosis growth in the lungs of gamma-
interferon gene knock-out (GKO) mice by anti-TB drugs
M. tuberculosis in the lungs of untreated GKO mice increased by
5.1 log10CFU from day 3 to day 24 post-infection while TBSA
increased by 1.74 mg/mouse from day 10 to day 24 post-infection.
TBSA in lung homogenates at day 3 post-infection was still below
the limit of detection. All three dosages of the ﬁve established and
experimental anti-TB drugs signiﬁcantly decreased the level of
TBSA in lung homogenates after 14 days treatment (except the low
dosage of 3.75mg/kg rifampin) comparedwith untreatedmice, and
did so in a dose-dependent manner (Figure 6AeB).
TBSA correlated well with CFU with an overall R2 value of 0.733
for all samples and 0.974 for only untreated controls. RMP andMOX
demonstrated the most proportional doseeresponse effects in both
TBSA and CFU (R2 > 0.8) (Figure 6C; Table 2).
4. Discussion
The ability to rapidly and accurately quantitateM. tuberculosis is
essential in anti-TB drug screening and useful in TB diagnosis. CFU
analyses, while representing the goal standard for quantitating
viable, cultivable bacilli, suffer from the tendency ofM. tuberculosis
to clump, long turnaround times and labor intensity. A number of
M. tuberculosis biomarkers have been proposed,20 some of which
may be candidates for quantitation employing modern analytical
chemistry instrumentation offering better precision and sensitivity
than conventional methods. In the case of TBSA analysis, we
detected as little as 40.5 pg (1012 g) of pure compound in a single
injection using GCeMS/MS.
The mycobacterial cell wall is a complex structure that accounts
for 60% of the cellular dry weight and consists primarily of a com-
bination of lipids and carbohydrates. Tuberculostearic acid is a lipid
tail of phosphatidyl-myo-inositol mannoside (PIMs) formed
Table 2
Correlation of drug dose and CFU or TBSA in GKO mouse infection model.
Drug R2
CFU TBSA
RMP 0.92 0.89
INH 0.59 0.68
MOX 0.91 0.88
PA 0.87 0.14
EMB 0.35 0.44
Figure 6. Growth and responses (day 24 after infection) of TBSA (A) and CFU (B) in M. tube
treatment with three dosages of ﬁve anti-TB drugs; drug dosages (mg/kg) used to treat infect
25 for INH, 8, 16, 32 for MOX, 25, 50, 100 for PA, and 100, 200, 400 for EMB in ﬁve replicates
line, y ¼ 0.41x  0.18, R2 ¼ 0.73) and in only untreated control samples (solid line, closed
G. Cai et al. / Tuberculosis 93 (2013) 322e329 327through the linkage of a phosphatidyl glycerol while PIMs are
lipopolysaccharides that directly associate with the M. tuberculosis
primary plasma membrane.21e23 Among the most abundant long
chain fatty acids containing 14e26 carbons, TBSA is detected in
most mycobacterial species but not in mammalian hosts.2,24,25 For
this reason detection of TBSA in clinical samples has been explored
as a diagnostic biomarker of TB.7e10,26,27 While these represent
semi-quantitative measurements of TBSA in human clinical sam-
ples, we are unaware of reports performing a validated andrculosis Erdman-infected GKO mice (combined right and left lung homogenates) after
ed GKO mice are (in the order of Low, Medium and High): 3.75, 7.5, 15 for RMP, 6.25, 15,
each dosage; (C) Overall correlation of log10CFU with log10TBSA in all samples (dashed
circles, y ¼ 0.55x  1.2, R2 ¼ 0.97).
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G. Cai et al. / Tuberculosis 93 (2013) 322e329328selective quantitation of TBSA from lung tissue, for use in animal
models. According to a recent report hexacosanoic acid (C26) can be
a secondary biomarker (in addition to TBSA) for M. tuberculosis in
sputum samples.8 We also monitored C26 as the methyl ester in our
in vitro samples and the response to INH and RMP was similar to
that seenwith TBSA (Figure 7). However concentrations of C26 were
approximately 100-fold lower than those of TBSA and provided no
additional advantage over monitoring of the latter.
In this studywe have validated TBSA as a quantitative biomarker
for M. tuberculosis in axenic medium, in macrophages and in the
lungs of infected mice. That TBSA persists afterM. tuberculosis is no
longer able to replicate was clearly evident when monitoring
growth in axenic medium. This is consistent with the fact that TBSA
is a chemically stable, intrinsic cell wall component. Likewise, once
bio-synthesized, TBSA persists, but does not further accumulate in
the presence of effective concentrations of bactericidal or bacter-
iostatic drugs. In both macrophage and GKO mouse experiments
there was a higher correlation of TBSA with CFU in M. tuberculosis
that was growing and not exposed to drugs vs. the correlation of
these parameters when considering both treated and untreated
cultures/mice. This is consistent with the observation that CFU
stops/declines more abruptly than TBSA after drug exposure likely
due to the persistence of the marker in dead cells. The stability of
TBSA in non-viableM. tuberculosis limits its utility in drug studies to
those that measure inhibition of growth and requires sufﬁcient
treatment duration such that signiﬁcant differences can be
observed between treated and untreated cells or mice. Therefore,
TBSA can serve as a bacteriostatic, but not a bactericidal biomarker.
For most drugs the concentration/dosages were highly corre-
lated with TBSA or CFU in both models (Tables 1 and 2) with the
exception of (1) EMB by CFU in the macrophage model and by both
readouts in the mouse model and (2) PA-824 in the mouse using
the TBSA readout where there was no further reduction at dosages
above 50mg/kg. The more pronounced dose-responses observed in
TB-infected macrophages compared to mice is possibly due to
a more direct correlation between the amount of drug applied and
the resulting exposure in the former. Although we failed to observe
any heightened sensitivity of TBSA synthesis vs. CFU overall with
respect to the response to individual drugs, the results with
ethambutol in both macrophages and mice suggested that some
degree of decreased TBSA might be tolerated without com-
promising viability. Ethambutol, a classical bacteriostatic drug, has
previously been shown to reduce both the amount of TBSA and
octadecenoic acid (18:1) in Mycobacterium vaccae growing in vitro.
Ethambutol inhibits the activity of arabinosyl transferase which inturn is responsible for glycosylation in the biosynthesis of the cell
wall-associated arabinogalactan and lipoarabinomannan,28 the
result of which is disorganization of the cell wall outer layer, loss of
cellular integrity and changes in free lipid composition.25
When using TBSA as the biomarker for M. tuberculosis viability
in drug screening assays, our goal is to distinguish at least a one
log10 difference between treated and untreated samples. The limit
of detection of the GCeMS/MS instrument used in this study
is w103 cells/ml broth and 104 cells per ml macrophage lysate or
per GKOmouse, rivaling the sensitivity of a reporter enzyme-based
ﬂuorescence method that can be used in live mice.29 At this level of
sensitivity, inhibition of growth in the lungs of mice by drugs could
easily be detected in immune-deﬁcient GKOmice, amodel enabling
high lung titers ofM. tuberculosis to be achieved prior to signiﬁcant
morbidity and mortality. Based on these results, TBSA-monitored
evaluation of drug activity in immune-competent mice should
also be feasible using currently available mass spectrometer up-
grades that increase sensitivity.
In summary GCeMS/MS based quantitation of TBSA is useful for
rapidly quantitating the degree of drug-mediated growth inhibition
of M. tuberculosis in vitro, in macrophage culture and in mice and
can be used with any strain without genetic manipulation. The
processing cost and time for analysis of 100 samples isw$100 and
24 h, respectively. The exceptional heat stability of TBSA enables
cultures to be autoclaved prior to analysis, simplifying downstream
processing and biosafety concerns.Funding: None.Competing interests: None declared.Ethical approval: Not required.References
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